Take a trial of UK to unlock this pageFind out more

« All RNS

GLAXOSMITHKLINE | Transaction In Own Shares | RNS

RNS Number : 5996X
GlaxoSmithKline PLC
16 February 2012

GlaxoSmithKline plc (the "Company") announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 5 May 2011 it purchased 420,000 of its Ordinary shares of 25 pence each ("shares") on 16 February 2012.


The highest price paid per share was 1,426.5 pence per share.

The lowest price paid per share was 1,404.0 pence per share.

The Company intends to hold these shares in Treasury.


The Company holds 502,862,927 of its shares in Treasury, representing 9.05% of the total issued share capital of the Company. 


Including shares which have been purchased but not yet settled, the Company holds 504,192,927 of its shares in Treasury, representing 9.98% of the total voting rights in the Company.


The Company has 5,050,618,069 shares in issue (excluding shares held in Treasury). This number represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.


This announcement does not constitute, or form part of, an offer or any solicitation of an offer to purchase or subscribe for securities in any jurisdiction and is in conformity with the Financial Services Authority's Disclosure and Transparency Rules.

This information is provided by RNS
The company news service from the London Stock Exchange

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc. more »

Share Price (Full)
-25.5  -1.7%
P/E (fwd)
Yield (fwd)
Mkt Cap (£m)